7 3 2 - 3 4 1 - 9 5 0 0
Mon - Fri
9AM-5PM
9 Mule Road, Suite 8, Toms River, NJ 08755

¤ Home » Clinical Trial » Clinical Trials at AMRINJ

Clinical Trials at AMRINJ

EVOLVE

Sponsor: Biogen
Protocol: 221AD205

Status: Active - Enrollment Open

A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Blind, Controlled Study of Aducanumab (BIIB037) in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Subjects With Asymptomatic Amyloid-Related Imaging Abnormalities.

Read more at www.ClinicalTrials.gov




Graduate

Sponsor: Hoffmann-La Roche
Protocol: WN29922

Status: Active - Enrollment Open

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in Patients With Prodromal to Mild Alzheimer's Disease.

Study Phase: 3

Route: Injection

Read more at www.ClinicalTrials.gov




Mission AD

Sponsor: Eisai in collaboration with Biogen
Protocol: E2609-G000-302

Status: Active - Enrollment Open

A Placebo-Controlled, Double –Blind, Parallel Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease.

Study Phase: 3

Route: Oral

Read more at www.ClinicalTrials.gov




ROAD

Sponsor: Hisun
Protocol: Hisun-AD-35-003

Status: Active - Enrollment Open

A Pilot, Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety and Tolerability, Efficacy, and Pharmacokinetics of AD-35 in Subjects with Mild to Moderate Alzheimer’s Disease.

Read more at www.ClinicalTrials.gov




Tango

Sponsor: Biogen
Protocol: 251AD201

Status: Active - Enrollment Open

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer's Disease or with Mild Alzheimer's Disease.

Study Phase: 2

Route: Infusion (IV)

Read more at www.ClinicalTrials.gov




Tauriel

Sponsor: Genentech
Protocol: GN39763

Status: Active - Enrollment Open

A Phase II, Multicenter, Randomized, Double-blind, placebo-controlled, parallel-group, efficacy, and safety study of MTAU9937A in patients with Prodromal to Mild Alzheimer’s Disease.

Study Phase: 2

Route: Infusion (IV)

Read more at www.ClinicalTrials.gov




Trailblazer

Sponsor: Eli Lilly
Protocol: I5T-MC-AACG

Status: Active - Enrollment Open

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in Patients With Prodromal to Mild Alzheimer's Disease.

Study Phase: 3

Route: Oral and Infusion (IV)

Read more at www.ClinicalTrials.gov




PERISCOPE

Sponsor: Eli Lilly
Protocol: I8G-MC-LMDC

Status: Upcoming

Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease.

Study Phase: 2

Route: Infusion (IV)

Read more at www.ClinicalTrials.gov




CREAD

Sponsor: Hoffmann-La Roche
Protocol: BN29552

Status: Active - Enrollment Closed

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease.

Study Phase: 3

Route: Infusion (IV)

Read more at www.ClinicalTrials.gov




CREAD 2

Sponsor: Hoffmann-La Roche
Protocol: BN29553

Status: Active - Enrollment Closed

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease.

Study Phase: 3

Route: Infusion (IV)

Read more at www.ClinicalTrials.gov




CREAD OLE

Sponsor: Hoffmann-La Roche
Protocol: BN40031

Status: Active - Enrollment Closed

A Multicenter, Open-Label, Long-Term Extension Of Phase III Studies (BN29552/BN29553) Of Crenezumab In Patients With Alzheimer's Disease.

Study Phase: Open Label Extension (OLE)

Route: Infusion (IV)

Read more at www.ClinicalTrials.gov




Eisai BAN2401

Sponsor: Eisai
Protocol: BAN2401-G000-201

Status: Active - Enrollment Closed

A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects with Early Alzheimer’s Disease.

Study Phase: 2

Route: Infusion (IV)

Read more at www.ClinicalTrials.gov




Engage

Sponsor: Biogen
Protocol: 221AD301

Status: Active - Enrollment Closed

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease.

Study Phase: 3

Route: Infusion (IV)

Read more at www.ClinicalTrials.gov and www.EngageAndEmerge.com




Prime

Sponsor: Biogen
Protocol: 221AD103

Status: Active - Enrollment Closed

A Randomized, Double-Blind, Placebo-controlled Multi Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in subjects With Prodromal or Mild Alzheimer’s Disease.

Study Phase: 1

Route: Infusion (IV)

Read more at www.ClinicalTrials.gov




SUVN-502

Sponsor: Suven Life Sciences Limited
Protocol: CTP2S1502HT6

Status: Active - Enrollment Closed

A Phase 2A Multicentre, Randomized, Double-Blind, Parallel Group, 23-Week, Placebo-Controlled Study of 50mg and 100mg of SUVN-502 in subjects with moderate Alzheimer’s Disease Currently treated with Donepezil hydrochloride and Mementin hydrochloride.

Study Phase: 2

Route: Oral

Read more at www.ClinicalTrials.gov




ABBY

Sponsor: Genentech, Inc.
Protocol: ABE4869g

Status: Closed

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study To Evaluate The Efficacy and Safety of MANT5102A In Patients with Mild to Moderate Alzheimer’s Disease.

Read more at www.ClinicalTrials.gov




ACTION

Sponsor: Novartis
Protocol: CENA713D US44

Status: Closed

A 24-week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study Comparing the Effects of Rivastigmine Patch 15cm vs. Rivastigmine Patch 5cm on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer’s Type (ACTION).

Read more at www.ClinicalTrials.gov




ACTION Extension

Sponsor: Novartis
Protocol: CENA713D US44E1

Status: Closed

A 24 Week Open-Label Extension to Study CENA713DUS44: A 24 Week, Prospective, Randomized, Parallel-Group, Double-blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer’s Type (ACTION).

Read more at www.ClinicalTrials.gov




Amaranth

Sponsor: Eli Lilly in collaboration with AstraZeneca
Protocol: D5010C0009 (I8D-MC-AZES)

Status: Closed

A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study).

Study Phase: 3

Route: Oral

Read more at www.ClinicalTrials.gov




Amaranth Extension

Sponsor: Eli Lilly in collaboration with AstraZeneca
Protocol: 18D-MC-AZFD

Status: Closed

A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study).

Study Phase: 3

Route: Oral

Read more at www.ClinicalTrials.gov




Avanir 12-AVR-131

Sponsor: Avanir Pharmaceuticals
Protocol: 12-AVR-131

Status: Closed

A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients with Alzheimer's Disease.

Read more at www.ClinicalTrials.gov




BMS CN156-018

Sponsor: Bristol-Myers Squibb
Protocol: CN156-018

Status: Closed

A Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal Alzheimer’s Disease.

Read more at www.ClinicalTrials.gov




CERESPIR CCD-1014-PR-0053

Sponsor: CERESPIR
Protocol: CCD-1014-PR-0053

Status: Closed

A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients with Mild Cognitive Impairment.

Read more at www.ClinicalTrials.gov




Charsire BAC-02

Sponsor: Charsire Biotechnology Corp.
Protocol: BAC-02

Status: Closed

A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate the Efficacy and Safety of BAC in Patient with Alzheimer’s disease or Vascular Dementia.

Study Phase: 2

Route: Topical Cream

Read more at www.ClinicalTrials.gov




DAYBREAK

Sponsor: Eli Lilly
Protocol: I8D-MC-AZET

Status: Closed

A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer’s disease Dementia (The DAYBREAK Study).

Study Phase: 3

Route: Oral

Read more at www.ClinicalTrials.gov and www.daybreak-alzstudy.com




Eisai E2006

Sponsor: Eisai in collaboration with Purdue Pharma LP
Protocol: E2006-G000-202

Status: Closed

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lemborexant in Subjects with Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer’s Disease Dementia.

Study Phase: 2

Route: Oral

Read more at www.ClinicalTrials.gov




FORUM EVP-6124-010

Sponsor: FORUM Pharmaceuticals Inc.
Protocol: EVP-6124-010

Status: Closed

A Randomized, Double-blind, Placebo-controlled, Parallel, 24-week, Adaptive Design Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects with Mild to Moderate Probable Alzheimer’s Disease.

Read more at www.ClinicalTrials.gov




IDEAS

Sponsor: American College of Radiology Imaging Network in collaboration with Alzheimer’s Association
Protocol: ACRIN7115 IDEAS

Status: Closed

Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage With Evidence Development Longitudinal Cohort Study.

Read more at www.ClinicalTrials.gov




Merck MK0000-318

Sponsor: Merck Sharp & Dohme Corp.
Protocol: MK0000-318

Status: Closed

A Clinical Trial to Assess Cognitive Function by Repeated Computerized Testing in Patients with Mild Alzheimer’s Disease Treated with Donepezil.

Read more at www.ClinicalTrials.gov




Merck MK7622-012

Sponsor: Merck Sharp & Dohme Corp.
Protocol: MK7622-012

Status: Closed

A Seamless Phase IIa/IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy to Donepezil for Symptomatic Treatment in Subjects with Alzheimer’s Disease.

Read more at www.ClinicalTrials.gov




Navigate AD

Sponsor: Eli Lilly
Protocol: I7X-MC-LLCF

Status: Closed

Effect of LY3202626 on Alzheimer’s Disease Progression as Measured by Cerebral 1451 Tau-PET in Mild Alzheimer’s Disease Dementia.

Study Phase: 2

Route: Oral

Read more at www.ClinicalTrials.gov




Nourish-AD

Sponsor: Accera, Inc.
Protocol: AC-12-010

Status: Closed

A 26-Week, Double-Blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants with Mild to Moderate Alzheimer’s Disease (AD) with an Optional 26-Week Open-label Extension.

Read more at www.ClinicalTrials.gov




Pfizer 3133K1-3000

Sponsor: Pfizer
Protocol: 3133K1-3000

Status: Closed

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN 115727) in Subjects with Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E e4 Non-Carriers.

Read more at www.ClinicalTrials.gov




RAmP Registry

Sponsor: Avid Radiopharmaceuticals in collaboration with Eli Lilly & PRA Health Sciences
Protocol: 18F-AV-45-A25

Status: Closed

Registry of Amyloid Positive Patients for Alzheimer’s Disease Drug Research Trials (RAmP).

Read more at www.ClinicalTrials.gov




ST101-A001-202

Sponsor: Sonexa Therapeutics, Inc.
Protocol: ST101-A001-202

Status: Closed

A Double-blind, Placebo-controlled, Preliminary Study of the Efficacy, Safety, and Tolerability of ST101 in the Treatment of Alzheimer’s Disease in Subjects Concurrently Receiving Donepezil (Aricept).

Read more at www.ClinicalTrials.gov




Shire 161003

Sponsor: Shire
Protocol: 161003

Status: Closed

A Phase III, Randomized, Double-blind, Placebo-controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (human), 10% solution (IGIV, 10%) for the treatment of mild to moderate Alzheimer’s disease (AD).

Read more at www.ClinicalTrials.gov




Shire 81-0067

Sponsor: Depomed
Protocol: 81-0067

Status: Closed

A Phase IV, Open Label, Study of Safety and Effectiveness of GRALISE (Gabapentin) Tablets in the Treatment of Patients with Post Herpetic Neuralgia in Clinical Practice.

Read more at www.ClinicalTrials.gov




Star Extension

Sponsor: H. Lundbeck
Protocol: 14861B

Status: Closed

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Lu AE58054 as Adjunctive Treatment to Acetylcholinesterase Inhibitors in Patients with Mild to Moderate Alzheimer´s Disease.

Read more at www.ClinicalTrials.gov




Starbright

Sponsor: H. Lundbeck
Protocol: 14863A

Status: Closed

Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lu AE58054 in Patients with Mild to Moderate Alzheimer’s Disease Treated with an Acetylcholinesterase Inhibitor.

Read more at www.ClinicalTrials.gov




Starshine

Sponsor: H. Lundbeck
Protocol: 14861A

Status: Closed

Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients with Mild to Moderate Alzheimer’s Disease Treated with Donepezil.

Read more at www.ClinicalTrials.gov




TauRX TRx-237-005

Sponsor: TauRX Therapeutics Ltd.
Protocol: TRx-237-005

Status: Closed

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of TRx0237 in Subjects with Mild Alzheimer's Disease.

Read more at www.ClinicalTrials.gov




TauRX TRx-237-015

Sponsor: TauRX Therapeutics Ltd.
Protocol: TRx-237-015

Status: Closed

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects with Mild to Moderate Alzheimer's Disease.

Read more at www.ClinicalTrials.gov




VIVUS AD-201

Sponsor: VIVUS, Inc.
Protocol: AD-201

Status: Closed

A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability, and Efficacy of VI-1121 in Subjects with Alzheimer’s Disease.

Read more at www.ClinicalTrials.gov